MENU
INMD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

INMD stock forecast, quote, news & analysis

InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions... Show more

INMD
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
A.I.Advisor
a Summary for INMD with price predictions
Jun 12, 2026

Momentum Indicator for INMD turns negative, indicating new downward trend

INMD saw its Momentum Indicator move below the 0 level on May 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned negative. In of the 96 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

INMD moved below its 50-day moving average on May 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for INMD crossed bearishly below the 50-day moving average on May 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for INMD entered a downward trend on May 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

INMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.289) is normal, around the industry mean (10.947). P/E Ratio (9.963) is within average values for comparable stocks, (63.393). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.718). INMD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (2.300) is also within normal values, averaging (23.694).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 5.43B. The market cap for tickers in the group ranges from 1.86K to 153.59B. ABT holds the highest valuation in this group at 153.59B. The lowest valued company is CSAY at 1.86K.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -1%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was -17%. SI experienced the highest price growth at 31%, while ICCM experienced the biggest fall at -45%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -38%. For the same stocks of the Industry, the average monthly volume growth was -41% and the average quarterly volume growth was 102%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 76
Price Growth Rating: 61
SMR Rating: 90
Profit Risk Rating: 95
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
INMD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of minimally-invasive aesthetic medical products

Industry MedicalNursingServices

Profile
Details
Industry
N/A
Address
Sha’ar Yokneam
Phone
+972 49096313
Employees
660
Web
https://www.inmodemd.com
Momentum Indicator for INMD turns negative, indicating new downward trend